Pirjo Laakkonen

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

Erkki Ruoslahti, Michele Bernasconi, Kimmo Porkka, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Homing peptides as targeted delivery vehicles.

P. Laakkonen, Pirjo Laakkonen, Kirsi Vuorinen, 2010, Integrative biology : quantitative biosciences from nano to macro.

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

Erkki Ruoslahti, Kimmo Porkka, Jason A. Hoffman, 2002, Nature Medicine.

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

Erkki Ruoslahti, Kimmo Porkka, Sven Christian, 2003, The Journal of cell biology.

Nanocrystal targeting in vivo

Erkki Ruoslahti, Sangeeta N. Bhatia, Warren C. W. Chan, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Identification and Characterization of Homing Peptides Using In Vivo Peptide Phage Display.

P. Laakkonen, M. Hyvönen, Pirjo Laakkonen, 2015, Methods in molecular biology.

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents

Karita Peltonen, K. Peltonen, M. Laiho, 2010, PloS one.

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression

Johanna Eriksson, P. Laakkonen, E. Hölttä, 2016, Oncotarget.

Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors

Heikki Joensuu, Ale Närvänen, Ulo Langel, 2014, Molecular Cancer Therapeutics.

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

Antonio Duarte, Gerhard Christofori, Seppo Ylä-Herttuala, 2008, Nature.